Joel Masopeh, Audra Garrigan, Kevin Heinsimer, Lucas Wiegand
{"title":"药物包被球囊扩张治疗放射相关性尿道狭窄的疗效。","authors":"Joel Masopeh, Audra Garrigan, Kevin Heinsimer, Lucas Wiegand","doi":"10.21037/tau-24-461","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The Optilume<sup>®</sup> drug-coated balloon is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The ROBUST III trial concludes that Optilume is safe and superior to standard direct vision internal urethrotomy/dilation for the treatment of recurrent anterior urethral strictures <3 cm in length. However, there have been limited studies to show efficacy in the treatment of urethral stricture in the setting of post-radiation patients. This study aimed to clarify the safety and early efficacy of Optilume balloon dilation for urethral strictures in post-radiation patients.</p><p><strong>Methods: </strong>All patients undergoing Optilume balloon dilation with at least 3 months of follow-up were evaluated over 27 months in a retrospective multi-institutional setting. Thirty patients who received pelvic radiation and subsequently developed symptomatic urethral strictures were selected from a total of 246 patients identified with symptomatic urethral strictures. Success was defined as the absence of recurrence of original presenting symptoms, no need for intermittent self-dilation, and no requirement for surgical intervention within the follow-up period for their urethral stricture.</p><p><strong>Results: </strong>Successful Optilume balloon dilations without recurrence of symptoms were achieved in 24/30 (80%) patients. Failures with recurrence of strictures occurred in 20% (6/30) of cases. At a median follow-up of 353 (range: 91-818) days, 80% (24/30) of radiated patients had successful Optilume balloon dilation. Our data showed that 83% (5/6) of patients who experienced recurrence did so after 12 months. Among radiated patients without baseline incontinence, new stress incontinence developed postoperatively in 20% (3/15), while one patient had improved stress incontinence.</p><p><strong>Conclusions: </strong>Optilume balloon dilation is a safe mechanism of treatment for urethral stricture disease in radiated patients. Early follow-up data of the treatment of urethral strictures in radiated patients suggests similar efficacy. However, long-term follow-up data is needed.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 8","pages":"2129-2134"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433151/pdf/","citationCount":"0","resultStr":"{\"title\":\"Outcomes of drug-coated balloon dilation in patients with radiation-related urethral stenosis.\",\"authors\":\"Joel Masopeh, Audra Garrigan, Kevin Heinsimer, Lucas Wiegand\",\"doi\":\"10.21037/tau-24-461\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The Optilume<sup>®</sup> drug-coated balloon is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The ROBUST III trial concludes that Optilume is safe and superior to standard direct vision internal urethrotomy/dilation for the treatment of recurrent anterior urethral strictures <3 cm in length. However, there have been limited studies to show efficacy in the treatment of urethral stricture in the setting of post-radiation patients. This study aimed to clarify the safety and early efficacy of Optilume balloon dilation for urethral strictures in post-radiation patients.</p><p><strong>Methods: </strong>All patients undergoing Optilume balloon dilation with at least 3 months of follow-up were evaluated over 27 months in a retrospective multi-institutional setting. Thirty patients who received pelvic radiation and subsequently developed symptomatic urethral strictures were selected from a total of 246 patients identified with symptomatic urethral strictures. Success was defined as the absence of recurrence of original presenting symptoms, no need for intermittent self-dilation, and no requirement for surgical intervention within the follow-up period for their urethral stricture.</p><p><strong>Results: </strong>Successful Optilume balloon dilations without recurrence of symptoms were achieved in 24/30 (80%) patients. Failures with recurrence of strictures occurred in 20% (6/30) of cases. At a median follow-up of 353 (range: 91-818) days, 80% (24/30) of radiated patients had successful Optilume balloon dilation. Our data showed that 83% (5/6) of patients who experienced recurrence did so after 12 months. Among radiated patients without baseline incontinence, new stress incontinence developed postoperatively in 20% (3/15), while one patient had improved stress incontinence.</p><p><strong>Conclusions: </strong>Optilume balloon dilation is a safe mechanism of treatment for urethral stricture disease in radiated patients. Early follow-up data of the treatment of urethral strictures in radiated patients suggests similar efficacy. However, long-term follow-up data is needed.</p>\",\"PeriodicalId\":23270,\"journal\":{\"name\":\"Translational andrology and urology\",\"volume\":\"14 8\",\"pages\":\"2129-2134\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433151/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational andrology and urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tau-24-461\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ANDROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational andrology and urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tau-24-461","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ANDROLOGY","Score":null,"Total":0}
Outcomes of drug-coated balloon dilation in patients with radiation-related urethral stenosis.
Background: The Optilume® drug-coated balloon is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The ROBUST III trial concludes that Optilume is safe and superior to standard direct vision internal urethrotomy/dilation for the treatment of recurrent anterior urethral strictures <3 cm in length. However, there have been limited studies to show efficacy in the treatment of urethral stricture in the setting of post-radiation patients. This study aimed to clarify the safety and early efficacy of Optilume balloon dilation for urethral strictures in post-radiation patients.
Methods: All patients undergoing Optilume balloon dilation with at least 3 months of follow-up were evaluated over 27 months in a retrospective multi-institutional setting. Thirty patients who received pelvic radiation and subsequently developed symptomatic urethral strictures were selected from a total of 246 patients identified with symptomatic urethral strictures. Success was defined as the absence of recurrence of original presenting symptoms, no need for intermittent self-dilation, and no requirement for surgical intervention within the follow-up period for their urethral stricture.
Results: Successful Optilume balloon dilations without recurrence of symptoms were achieved in 24/30 (80%) patients. Failures with recurrence of strictures occurred in 20% (6/30) of cases. At a median follow-up of 353 (range: 91-818) days, 80% (24/30) of radiated patients had successful Optilume balloon dilation. Our data showed that 83% (5/6) of patients who experienced recurrence did so after 12 months. Among radiated patients without baseline incontinence, new stress incontinence developed postoperatively in 20% (3/15), while one patient had improved stress incontinence.
Conclusions: Optilume balloon dilation is a safe mechanism of treatment for urethral stricture disease in radiated patients. Early follow-up data of the treatment of urethral strictures in radiated patients suggests similar efficacy. However, long-term follow-up data is needed.
期刊介绍:
ranslational Andrology and Urology (Print ISSN 2223-4683; Online ISSN 2223-4691; Transl Androl Urol; TAU) is an open access, peer-reviewed, bi-monthly journal (quarterly published from Mar.2012 - Dec. 2014). The main focus of the journal is to describe new findings in the field of translational research of Andrology and Urology, provides current and practical information on basic research and clinical investigations of Andrology and Urology. Specific areas of interest include, but not limited to, molecular study, pathology, biology and technical advances related to andrology and urology. Topics cover range from evaluation, prevention, diagnosis, therapy, prognosis, rehabilitation and future challenges to urology and andrology. Contributions pertinent to urology and andrology are also included from related fields such as public health, basic sciences, education, sociology, and nursing.